Tyrosine kinase inhibitors (TKIs) are the standard of care for patients with non-small cell lung
cancer (NSCLC) that harbor mutations of the epidermal growth factor receptor (EGFR) gene …

Abstract Most advanced Non–Small-cell lung cancers (NSCLCs) with activating epidermal
growth factor receptor (EGFR) mutations (exon 19 deletions or L858R) initially respond to …

Background Epidermal growth factor receptor (EGFR) mutations are present in the majority
of patients with non-small cell lung cancer (NSCLC) responsive to the EGFR tyrosine kinase …

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib
and erlotinib are promising therapies for patients with advanced non-small-cell lung cancer …

Non-small-cell lung cancer (nsclc) has the highest prevalence of all types of lung cancer,
which is the second most common cancer and the leading cause of cancer-related mortality …

Purpose: Most lung cancers with activating epidermal growth factor receptor (EGFR)
mutations respond to gefitinib; however, resistance to this tyrosine kinase inhibitor (TKI) …

Introduction The efficacy of high-dose (1250 mg/d) gefitinib for the treatment of
leptomeningeal metastasis in a patient with lung cancer harboring a mutation in the …

Non-small cell lung cancer (NSCLC) tumours with certain mutations in the epidermal growth
factor receptor (EGFR) tyrosine kinase have been termed 'oncogene addicted'to reflect their …

Identification of EGFR mutations is critical to the treatment of primary lung cancer and brain
metastases (BMs). Here, we explored whether radiomic features of contrast-enhanced T1 …

Abstract Treatment for non-small-cell lung cancer (nsclc) is moving away from traditional
chemotherapy toward personalized medicine. The reversible tyrosine kinase inhibitors (tkis) …